Part 2 Consents
On 6/11/2012, the FTC required Johnson & Johnson (J&J) to sell its system for surgically treating serious wrist fractures, resolving charges that J&J's proposed $21.3 billion acquisition of Synthes, Inc. would illegally reduce competition for these systems. J&J intends to sell its system, known as DVR, along with the rest of its product line for treating traumatic injuries, to Biomet, Inc. According to the FTC's complaint, J&J's proposed acquisition of Synthes would harm competition in the U.S. market for volar distal radius plating systems, internal devices that are surgically implanted on the underside of the wrist to achieve proper alignment of the radius bone following a fracture. On 08/07/2012, the FTC approved a final order settling charges that Johnson & Johnson's proposed acquisition of Synthes, Inc. would have been anticompetitive in the market for surgical systems used to treat traumatic distal radius wrist fractures. The final FTC order resolving the charges requires Johnson & Johnson to sell its system for surgically treating serious wrist fractures.